Prof. Dr. Markus Essler
Clinic for Nuclear Medicine
klinik.nuklearmedizin@ukbonn.de View member: Prof. Dr. Markus Essler
Diagnostics (Basel, Switzerland)
Nanobodies are small recombinant antigen-binding fragments derived from camelid heavy-chain only antibodies. Due to their compact structure, pharmacokinetics of nanobodies are favorable compared to full-size antibodies, allowing rapid accumulation to their targets after intravenous administration, while unbound molecules are quickly cleared from the circulation. In consequence, high signal-to-background ratios can be achieved, rendering radiolabeled nanobodies high-potential candidates for imaging applications in oncology, immunology and specific diseases, for instance in the cardiovascular system. In this review, a comprehensive overview of central aspects of nanobody functionalization and radiolabeling strategies is provided.
PMID: 34573872
Clinic for Nuclear Medicine
klinik.nuklearmedizin@ukbonn.de View member: Prof. Dr. Markus Essler